瑞士诺华的地拉罗司用药注意事项

The chemical name of (deferasirox) is 4-[3,5-bis(2-hydroxyphenyl)-1,2,4-triazol-1-yl]benzoic acid. It is an iron chelator product developed by the Swiss pharmaceutical company Novartis. It is the first oral iron-removing agent approved by the US FDA for routine use. Deferasirox is a tridentate iron chelator that combines with ferric ions in a 2:1 ratio to form a complex that is excreted in the feces, thereby reducing iron storage in the body. Due to the continued presence of deferasirox in plasma, plasma non-transferrin-bound iron can be continuously reduced and the iron formed by toxicity in the body can be directly eliminated.

Precautions when taking Deferasirox:

1. Deferasirox may cause rash. Generally, the rash will disappear automatically without the need to adjust the dose or stop the medication. If the condition is serious or persistent, the medication should be stopped.

2. The patient’s vision or hearing may be affected.

3. It should be taken 30 minutes before meals.

4. It should be taken at the same time every day.

Currently, the one most favored by patients is the one produced by Novartis in Switzerland. Novartis is a pharmaceutical and biotechnology multinational company headquartered in Basel, Switzerland. Its core businesses are in various patent medicines, consumer healthcare, generic medicines, eye care and animal health. According to Medical Companion Travel, the specification of Deferasirox from Novartis Switzerland is 400mg*30 tablets, but the price is only 420$, which is more suitable for patients for long-term use. Since the exchange rate is not static, the price will also fluctuate. For details, please consult Medical Companion Travel.

Recommended related hot articles: /newsDetail/94094.html

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.